A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): Study protocol

Trials

Volumn 14, Issue 1, 2013, Pages

  Mullen, Michael J ^a   Flather, Marcus D ^b   Jin, Xu Y ^c   Newman, William G ^d   Erdem, Guliz ^e   Gaze, David ^f   Valencia, Oswaldo ^f   Banya, Winston ^e   Foley, Claire E ^e   Child, Anne ^f  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRILLIN 1; IRBESARTAN; LOSARTAN; PLACEBO; PROPRANOLOL; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AORTA DILATATION; AORTA DISEASE; AORTA ROOT; ARTICLE; BLOOD VESSEL DIAMETER; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HUMAN; MARFAN SYNDROME; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCHOOL CHILD; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AORTA; AORTIC ANEURYSM; BIPHENYL COMPOUNDS; CHILD; CLINICAL PROTOCOLS; DILATATION, PATHOLOGIC; DOUBLE-BLIND METHOD; GREAT BRITAIN; HUMANS; MARFAN SYNDROME; PROSPECTIVE STUDIES; RESEARCH DESIGN; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888337753     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-408     Document Type: Article

References (40)

1. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996, 62:417-426. 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R, 8723076.
2. Loeys BL, Dietz HC, Braverman AC, Callewart BL, De Backer J, Deverux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010, 47:476-485. 10.1136/jmg.2009.072785, 20591885.
3. Child AH, Neumann L, Robinson PN. Diagnosis and treatment of Marfan syndrome - a summary. Marfan Syndrome: A Primer for Clinicians and Scientists 2004, Berlin: Springer, Robinson PN, Godfrey M.
4. Comeglio P, Evans AL, Brice G, Cooling RJ, Child AH. Identification of FBN1 gene mutations in patients with ectopia lentis and marfanoid habitus. Br J Ophthalmol 2002, 86(12):1359-1362. 10.1136/bjo.86.12.1359, 1771443, 12446365.
5. Collod-Beroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A, Comeglio P, De Paepe A, Hyland JC, Holman K, Kaitila I, Loeys B, Matyas G, Nuytinck L, Peltonen L, Rantamaki T, Robinson P, Steinmann B, Junien C, Béroud C, Boileau C. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 2003, 22(3):199-208. 10.1002/humu.10249, 12938084.
6. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, Stetten G, Meyers DA, Francomano CA. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991, 352:337-339. 10.1038/352337a0, 1852208.
7. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFFBR1 or TGFBR2. Nat Genet 2005, 37:275-281. 10.1038/ng1511, 15731757.
8. Mizuguchi T, Matsumo N. Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J Hum Genet 2007, 52:1-12.
9. Pannu H, Fadulu V, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro PF, Zaleski C, Estrera AL, Safi HY, Shete S, Willing MC, Raman CS, Milewicz DM. Mutations in transforming growth factor-B receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005, 112:513-520. 10.1161/CIRCULATIONAHA.105.537340, 16027248.
10. Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med 1972, 286(15):804-808. 10.1056/NEJM197204132861502, 5011789.
11. Gott VL, Cameron DE, Alejo DE, Greene PS, Shake JG, Caparrelli DJ, Dietz HC. Aortic root replacement in 271 Marfan patients: A 24 year experience. Ann Thorac Surg 2002, 73(2):438-443. 10.1016/S0003-4975(01)03336-7, 11845856.
12. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long term beta adrenergic blockade in Marfan's syndrome. N Engl J Med 1994, 330(19):1335-1341. 10.1056/NEJM199405123301902, 8152445.
13. Groenink M, de Roos A, Mulder BJ, Spaan JA, van der Wall EE. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1988, 82(2):203-208.
14. Haouzi A, Berglund H, Pelikan PC, Maurer G, Siegel RJ. Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. Am Heart J 1997, 133(1):60-63. 10.1016/S0002-8703(97)70248-5, 9006291.
15. Cameron D, Dresher JT. Management of Paediatric Aortic Disease in Marfan syndrome 2005, Ghent: 7th International Research Symposium on the Marfan syndrome, Oral presentation I.31.
16. Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P. Life expectancy in the Marfan syndrome. Am J Cardiol 1995, 75(2):157-160. 10.1016/S0002-9149(00)80066-1, 7810492.
17. Gersony DR, McClaughlin MA, Jin Z, Gersony WM. The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: A meta-analysis. Int J Cardiol 2005, 114(2007):303-308.
18. Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, Bunton T, Jensen Biery N, Dietz HC, Sakai LY, Ramirez F. Pathogenetic sequence for aneurysm revealed in mice under expressing fibrillin-1. Proc Natl Acad Sci U S A 1999, 96:3819-3823. 10.1073/pnas.96.7.3819, 22378, 10097121.
19. Ramirez F, Sakai LY, Dietz HC, Rifkin DB. Fibrillin microfibrils; multipurpose extra-cellular networks in organismal physiology. Physiol Genomics 2004, 19:151-154. 10.1152/physiolgenomics.00092.2004, 15466717.
20. Bunton TE, Jensen Biery N, Gayraud B, Ramirez F, Dietz HC. Phenotypic modulation of vascular smooth muscle cells contributes to elastolysis in a mouse model of Marfan syndrome. Circul Res 2001, 88:37-43.
21. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33:407-411. 10.1038/ng1116, 12598898.
22. Ng CM, Cheng A, Myers LA, Martinex-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004, 114:1586-1592. 529498, 15546004.
23. Jones KB, Myers L, Judge DP, Kirby PA, Dietz HC, Sponseller PD. Toward an understanding of dural ectasia: A light microscopy study in a murine model of Marfan syndrome. Spine 2005, 30:291-293. 10.1097/01.brs.0000152166.88174.1c, 15682009.
24. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312(5770):117-121. 10.1126/science.1124287, 1482474, 16601194.
25. Brenner BM, Cooper ME, De Zeeuw D, Grundfeld J-P, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S,. RENAAL Study Investigators The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin 11 Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000, 1(4):328-335. 10.3317/jraas.2000.062, 11967819, RENAAL Study Investigators.
26. Dahlof B, Devereux RB, Kjeldsen SE, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003. 10.1016/S0140-6736(02)08089-3, 11937178.
27. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn S, Zhang Z, Shahinfar S. Effects of Losartan on renal and cardiovascular outcomes in patient with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. 10.1056/NEJMoa011161, 11565518.
28. Tanaka H, Oki T, Tabata T, Yamada H, Harada K, Kimura E, Oishi Y, Ishimoto T, Ito S. Losartan improves regional left ventricular systolic and diastolic function in patients with hypertension: Accurate evaluation using a newly developed colour-coded tissue doppler imaging technique. J Card Fail 2004, 10(5):412-420. 10.1016/j.cardfail.2004.01.007, 15470652.
29. Williams B. Angiotensin II and the pathophysiology of cardiovascular remodelling. Am J Cardiol 2001, 87:10C-17C. 10.1016/S0002-9149(01)01507-7, 11334763.
30. Rosenkranz S. TGF-β1 and angiotensin networking in cardiac remodelling. Cardiovasc Res 2004, 63:423-432. 10.1016/j.cardiores.2004.04.030, 15276467.
31. Brooke BS, Habashi MD, Judge DP, Patel N, Loeys B, Dietz HC. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008, 358:2787-2795. 10.1056/NEJMoa0706585, 2692965, 18579813.
32. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ApRhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007, 13(2):204-210. 10.1038/nm1536, 3138130, 17237794.
33. Tiecke F, Robinson P, Booms P, Katze S, Hagemeier C, Neumann L, Hinkel G, Brenner R, Hovels-Gürich H, Fuchs J, Skovby F, Rosenberg T. Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet 2001, 9:13-21. 10.1038/sj.ejhg.5200582, 11175294.
34. Elçioglu NH, Akalin F, Elçioglu M, Comeglio P, Child AD. Neonatal Marfan syndrome caused by an Exon 25 mutation of the Fibrillin-1 gene. Genet Couns 2004, 15(2):219-225.
35. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faive U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S,. LIFE Study Group Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE); a randomised trial against atenolol. Lancet 2002, 359(9311):1004-1010. 10.1016/S0140-6736(02)08090-X, 11937179, LIFE Study Group.
36. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H. LIFE (Losartan Intervention for Endpoint Reduction) Study Group: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002, 288(12):1491-1498. 10.1001/jama.288.12.1491, 12243636.
37. Weber MA, Byyny RE, Pratt JH, Faison EP, Duane BS, Goldberg AI, Nelson EB. Blood pressure effects of the angiotensin 11 receptor blocker, Losartan. Arch Intern Med 1995, 155:405-411. 10.1001/archinte.1995.00430040081010, 7848024.
38. Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich L, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul P, Stylianou MP, Mahony L,. Pediatric Heart Network Investigators Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 2007, 154:624-631. 10.1016/j.ahj.2007.06.024, 3042860, 17892982, Pediatric Heart Network Investigators.
39. Robinson PN, Booms P, Katzke S, Ladewig M, Neumann L, Palz M, Pregla R, Tiecke F, Rosenberg T. Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 2002, 20(3):153-161. 10.1002/humu.10113, 12203987.
40. Faivre L, Collod-Beroud G, Loeys B, Child AH, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Robinson PN, Ades LC, Biggin A, Benetts B, Brett M, Holman KJ, De Backer J, Coucke P, Francke U, De Paepe A, et al. Effect of mutation type and location on clinical outcome in 1013 probands with Marfan syndrome or related phenotypes with FBN1 mutations: an international study. Am J Hum Genet 2007, 81(3):454-466. 10.1086/520125, 1950837, 17701892.